When was Anthos Therapeutics founded?

Anthos Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Anthos Therapeutics located?

Anthos Therapeutics is headquartered in Cambridge, United States.

Who is the current CEO of Anthos Therapeutics?

Bill Meury of Anthos Therapeutics.

How many employees does Anthos Therapeutics have?

As of Apr 30, 2026, the latest employee count at Anthos Therapeutics is 16.

Is Anthos Therapeutics a funded company?

Anthos Therapeutics is a funded company, having raised a total of $250M in its 1st and only funding round, a PE round on Feb 28, 2019.

How much is Anthos Therapeutics worth?

The last known valuation of Anthos Therapeutics was $3.1B as of Feb 11, 2025.

When was the latest funding round of Anthos Therapeutics?

Anthos Therapeutics' latest funding was a $250M PE round on Feb 28, 2019, with participation from 2 investors.

Is Anthos Therapeutics a Cardiac and Vascular Disorders company?

The primary sectors of Anthos Therapeutics are Cardiac and Vascular Disorders, Hematology and Immunotherapy.

Where does Anthos Therapeutics rank among its competitors?

Anthos Therapeutics ranks 15th amongst 220 active competitors, of which 73 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Halozyme, which secured $625M in Aug, 2022.

Who are the top competitors of Anthos Therapeutics?

Anthos Therapeutics' top competitors include Alexion, argenx and MacroGenics. Among them, Halozyme secured the most recent funding round in August, 2022.

Anthos Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Anthos Therapeutics is an acquired company based in Cambridge (United States), founded in 2019 by Jonathan Freeman and Paris Panayiotopoulos. It operates as a Developer of novel anticoagulants for thrombosis treatment. Anthos Therapeutics has raised $250M in funding from Blackstone and Novartis, with last known valuation of $3.1B. The company has 220 active competitors, including 73 funded and 59 that have exited. Its top competitors include companies like Alexion, argenx and MacroGenics.

Sectors and market segments that Anthos Therapeutics operate in

Anthos Therapeutics serves in the Life Sciences market segments.The primary business model of Anthos Therapeutics are:

Company Details

Developer of novel anticoagulants for thrombosis treatment. The company focuses on addressing unmet needs in anticoagulant therapy, particularly in areas like atrial fibrillation and cancer-associated thrombosis. Its lead product is a novel anticoagulant designed to reduce bleeding risks compared to existing therapies. Research and development efforts are centered on improving treatment options for patients at risk of thrombotic events. The company's approach is based on extensive clinical research and a deep understanding of hemostasis.

Website: anthostherapeutics.com
Email ID: *****@anthostherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2019

Location

Cambridge, United States

Stage

Acquired

Total Funding

$250M in 1 round

Latest Funding Round

PE, Feb 28, 2019, $250M

Last Known Valuation

$3.1B as on Feb 11, 2025

Investors

Blackstone & 4 more

Ranked

15^th among 220 active competitors

Employee Count

16 as on Apr 30, 2026

Similar Companies

Alexion & 265 more

Exit Details

Acquired by Novartis (Feb 11, 2025)

View Anthos Therapeutics' full profile

Anthos Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ANTHOS THERAPEUTICS, INC. CIN: 83-0933576 , United States, Active	Jun 17, 2018	-	14 (As on Dec 31, 2023)	-

Anthos Therapeutics got acquired by Novartis on Feb 11, 2025 at an acquisition amount of $*****.

Click here to take a look at Anthos Therapeutics's acquisition in detail

Anthos Therapeutics has raised a total funding of $250M over 1 round. Its latest funding round was a PE round on Feb 28, 2019 for $250M. 2 investors participated in its latest round. Anthos Therapeutics has 5 institutional investors.

Here is the list of recent funding rounds of Anthos Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 28, 2019	$250M	PE	-	-	Blackstone, Novartis	-

Access funding benchmarks and valuations. Sign up today!

View details of Anthos Therapeutics's funding rounds and investors

The founders of Anthos Therapeutics are Jonathan Freeman and Paris Panayiotopoulos. Bill Meury is the CEO of Anthos Therapeutics.

Here are the details of Anthos Therapeutics' key team members:

Jonathan Freeman: Co-Founder & COO of Anthos Therapeutics.
Contact Info: 1 email address
Paris Panayiotopoulos: Co-Founder of Anthos Therapeutics.
Bill Meury: CEO of Anthos Therapeutics.
Contact Info: 2 email addresses

View details of Anthos Therapeutics's Founder profiles and Board Members

Anthos Therapeutics' employee count trend

Anthos Therapeutics has 16 employees as of Apr 26. Here is Anthos Therapeutics's employee count trend over the years:

Employee count trend for Anthos Therapeutics

Uncover Anthos Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anthos Therapeutics include Alexion, argenx and MacroGenics. Here is the list of Top 10 competitors of Anthos Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Permira & 9 others	79/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	76/100
3rd	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
4th	CytomX Therapeutics 2008, Santa Barbara (United States), Public	Developing probody therapeutics to treat cancer	$136M	Fidelity Investments, Canaan & 14 others	70/100
5th	Zai Lab 2013, Shanghai (China), Public	Developer of drugs for anti-cancer and anti-inflammatory diseases	$160M	HongShan, Vivo Capital & 8 others	69/100
6th	Kodiak Sciences 2009, Palo Alto (United States), Public	Developer of therapeutics to treat retinal diseases	$35.8M	ArrowMark Partners, Perceptive Advisors & 1 others	66/100
7th	XOMA Corporation 1981, Berkeley (United States), Public	Developer of antibody-based therapeutics for treating endocrine/metabolic diseases	-	Ignite 500, Hercules Capital & 5 others	66/100
8th	BigHat 2019, San Carlos (United States), Series B	Provider of antibody therapies developed by machine learning and synthetic biology	$148M	Andreessen Horowitz, S32 & 13 others	64/100
9th	ABL Bio 2016, Seongnam-si (South Korea), Public	Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases	$65M	QUAD, Hana Financial Group & 7 others	64/100
10th	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, Athyrium Capital Management ... & 8 others	63/100
15th	Anthos Therapeutics 2019, Cambridge (United States), Acquired	Developer of novel anticoagulants for thrombosis treatment	$250M	Novartis, Nan Fung Life Sciences & 3 others	50/100